BeyondSpring Inc. (BYSI )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol BYSI
- Company BeyondSpring Inc.
- Price $0.64
- Changes Percentage 24.6
- Change 0.1271
- Day Low $0.5
- Day High $0.67
- Year High $2.44
- Year Low $0.57
- Market Cap $29,811,870
- Price Avg 50 EMA (D) $0.86
- Price Avg 200 EMA (D) $1.43
- Exchange NASDAQ
- Volume 17,602
- Average Volume 693,687
- Open $0.6
- Previous Close $0.52
- EPS -0.17
- PE -4.20
- Earnings Announcement 2026-11-12 20:00:00
- Shares Outstanding $41,119,820
Company brief: BEYONDSPRING INC. (BYSI )
- Healthcare
- Biotechnology
- Dr. Lan Huang Ph.D.
- https://www.beyondspringpharma.com
- US
- N/A
- 03-09-2017
- KYG108301006
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell lung cancer. It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of SCLC; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. The company was founded in 2010 and is headquartered in New York, New York.